Yarrow Bioscience Inc (YARW) Stock Ticker
YARW right now
Market factors today
Unlock the full YARW picture
About Yarrow Bioscience Inc
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
YARW stock facts
| Ticker symbol | YARW |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $412,704 |
| CEO | Rebecca Velez Frey |
| Employees | 10 |
| Headquarters | New Haven, CT, US |
| IPO date | 2026-07-28 |
| Website | www.yarrowbioscience.com |
What you can see for YARW on Tickr
Live YARW price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the YARW report.
Rankings
FAQ
What is the ticker symbol for Yarrow Bioscience Inc?
The ticker symbol for Yarrow Bioscience Inc is YARW, listed on the NASDAQ.
What is YARW?
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye…